Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …

Inflammation is substantially contributing to the development and worsening of diabetic
retinopathy in general and diabetic macular edema (DME) in particular, which provides the …

Purpose: To investigate efficacy and safety of repeated dexamethasone (DEX) implants over
24 months, in diabetic macular edema (DME) eyes that were treatment naive compared with …

Management of center-involving diabetic macular edema represents a real therapeutic
challenge. Diabetic macular edema is the leading cause of visual acuity impairment in …

Introduction Systematic review of real-world studies about repeated dexamethasone
intravitreal implant (DEXi) 0.7 mg in diabetic macular edema management, in order to …

Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite
that DME represents a sight‐threatening condition, it is also among the most accessible to …

Objectives of the Study. Summary of observational studies concerning the pharmacological
management of diabetic macular edema (DME). Methods. A literature review was conducted …

Diabetic macular edema (DME) is a chronic condition with a multifactorial pathogenesis.
Vascular endothelial growth factor (VEGF) and several inflammatory mediators are …

Purpose To evaluate the efficacy, effect profile, and safety of dexamethasone implant on
diabetic macular edema (DME) in a real-life setting, further comparing results by DME …

Aims To provide 2-year follow-up data on eyes with diabetic macular edema (DME) that
were non-responsive after three initial anti-vascular endothelial growth factor (VEGF) …